Patent case: G.D. Searle v. Sandoz B.V., Netherlands

Kluwer Patent Blog
April 9, 2019

Please refer to this post as: , ‘Patent case: G.D. Searle v. Sandoz B.V., Netherlands’, Kluwer Patent Blog, April 9 2019,

The Court concluded that the compound darunavir was not protected by a patent within the sense of Art. 3 of the SPC directive because, following the CJEU decision in Teva v Gilead, it is necessary that the compound for which the SPC is granted can be specifically identified in the patent.

Case date: 08 January 2019
Case number: C/09/56199 / KG ZA 18-1112
Court: Provisions Judge of the District Court of The Hague

A full summary of this case has been published on Kluwer IP Law.